Jack Hoadley
Learn more about Jack Hoadley

Jack Hoadley is a health policy analyst and political scientist with 30 years experience in the health policy field. He joined Georgetown University’s Health Policy Institute in 2002, where he conducts research on health financing topics, including Medicare and Medicaid, with a particular focus on prescription drug issues. Dr. Hoadley was recently appointed to a three-year term as a member of the Medicare Payment Advisory Commission (MedPAC). Prior to arriving at Georgetown, Dr. Hoadley held positions at the Department of Health and Human Services in the Office of the Assistant Secretary for Planning and Evaluation (ASPE); the Physician Payment Review Commission (PPRC) and its successor (MedPAC); the National Health Policy Forum at George Washington University; and in the office of U.S. Representative Barbara Kennelly.


While at Georgetown, Dr. Hoadley has undertaken projects for a variety of government and foundation clients, including the Kaiser Family Foundation, the Commonwealth Fund, the Jessie Ball duPont Fund, the Robert Wood Johnson Foundation, MedPAC, and DHHS/ASPE. In recent projects, he has studied various aspects of the Medicare Part D drug benefit, including spending trends, the use of formularies, the impact of the coverage gap, and policy options for simplifying and standardizing the program. His reports for the Kaiser Family Foundation on Medicare Part D spending, the coverage gap, and plan benefit design have received considerable attention from both media and policymakers. Findings from a new analysis of Part D claims data to assess what factors influence decisions to use generic drugs will be published in the near future. His other recent work has included projects on Medicaid reform proposals in Florida and Connecticut, consumer protections around balance billing in private insurance plans, standardization options for Medicare Advantage, the growth of retainer-based medical practices, and access to physician services for Medicare beneficiaries.


During his time in ASPE, Dr. Hoadley played a key role in the development of legislative options for Medicare modernization, especially a prescription drug benefit. He headed a Department team that released a report in April 2000, “Prescription Drug Coverage, Spending, Utilization, and Prices.” During his time at PPRC and MedPAC, Dr. Hoadley was a lead contributor to the Commission’s annual reports, including analysis of trends and developments in Medicare managed care, risk adjustment, health system reform, and Medicaid managed care.


Dr. Hoadley received his Ph.D. in political science from the University of North Carolina at Chapel Hill in 1979. He taught political science at Duke University and at the State University of New York at Stony Brook before coming to Washington as an American Political Science Association Congressional Fellow in 1983-84. He has published one book, Origins of American Political Parties, 1789-1803, and several articles in professional journals.


Recent Posts by Jack Hoadley

The Cost Of A Cure: Medicare’s Role In Treating Hepatitis C

For a patient with hepatitis C, a potentially deadly disease, the prospect of finding a cure with minimal side effects is a really big deal. Also a big deal is the cost of Sovaldi (sofosbuvir), an oral drug approved by the Food and Drug Administration in December 2013 for the treatment of...

Assessing A CMS Proposal To Improve Competition Among Medicare Part D Drug Plans

In one provision of its January Notice of Proposed Rulemaking (NPRM), for Medicare Part D and Medicare Advantage, CMS proposed that it will accept no more than two stand-alone prescription drug plan (PDP) bids from each Part D plan sponsor, starting in coverage year 2016. The agency stated two...

The Medicare Part D Drug Rebate Proposal: Rebutting An Unpersuasive Critique

A proposal to require manufacturers to pay a minimum rebate on drugs covered under Medicare Part D for those beneficiaries who receive the program’s Low-Income Subsidy (LIS) has received considerable attention during the current debate over the federal budget. Through mandating discounts in...